es a valid OMP as

				Complete if Known		
Substitute f	or form 144	9/PTO		Application Number	10/698,076	
INFORMATION DISCLOSURE				Filing Date	October 29, 2003	
STATEMENT BY APPLICANT				First Named Inventor	Cynthia B. Robinson	
(Use a	(Use as many sheets as necessary)		Art Unit	1617		
			Examiner Name	Umamaheswari Ramachandran		
Sheet	1	Of	4	Attorney Docket Number	30775-714.201	

THE DATES TO CHARACTE

Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US 2003/0216329	11/20/2003	Robinson et al.	
	2.	US 2004/0067920	04/08/2004	Leonard et al.	
	3.	US 2004/0082522	04/29/2004	Hui	
	4.	US 2005/0101544	05/12/2005	Robinson, et al.	
	5.	US 3,536,809	10/27/1970	Applezweig	
	6.	US 3,598,123	08/10/1971	Zaffaroni	
	7.	US 3,630,200	12/28/1971	Higuchi, et al.	
	8.	US 3,845,770	11/05/1974	Theeuwes, et al.	
	9.	US 3,916,899	11/04/1975	Theeuwes, et al.	
	10.	US 4,008,719	02/22/1977	Theeuwes, et al.	
	11.	US 4,208,423	06/17/1980	Pfister	
	12.	US 4,501,729	02/26/1985	Boucher et al.	
	13.	US 4,859,692	08/22/1989	Bernstein, et al	
	14.	US 4,956,355	09/11/1990	Prendergast	
	15.	US 5,294,636	03/15/1994	Edwards, et al.	
	16.	US 5,319,097	06/07/1994	Holohan, et al.	
	17.	US 5,482,963	01/09/1996	Holohan, et al.	
	18.	US 5,527,789	06/18/1996	Nyce	
	19.	US 5,565,473	02/23/1995	Belley, et al.	
	20.	US 5,583,152	12/10/1996	Bernstein, et al	
	21.	US 5,603,918	02/18/1997	McNamara	
	22.	US 5,612,367	03/18/1997	Timko, et al.	
	23.	US 5,660,835	08/26/1997	Nyce	
	24.	US 5,859,000	01/12/1999	Dowell et al.	
	25.	US 5,955,058	09/21/1999	Jager et al.	

ı	Signature				Considered	
•	EXAMINER: In	itial if reference considered, wi	bether or not citation is in	conformance with MPEP 6	9. Draw line through	citation if not in conformance and not considered. Include copy
	of this form with nex	ct communication to applicant.	Applicant's unique citat	tion designation number (opt	onal) ² See Kinds Cod	les of USPTO Patent Documents at www.uspto.gov or MPEP

Date

of this flow with next communication to applicate. Applicately suspect examon engagement names represently—with a name of the control of the

PTO/SB/08 (07/05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number

				Complete if Known		
Substitute f	or form 144	9/PTO		Application Number	10/698,076	
INFORMATION DISCLOSURE				Filing Date	October 29, 2003	
STATEMENT BY APPLICANT				First Named Inventor	Cynthia B. Robinson	
(Use a	(Use as many sheets as necessary)		Art Unit	1617		
			Examiner Name	Umamaheswari Ramachandran		
Sheet	2	Of	4	Attorney Docket Number	30775-714.201	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	26.	US 6,087,351	07/11/2000	Nyce		
	27.	US 6,143,775	11/07/2000	Holohan, et al.		
	28.	US 6,299,861	10/09/2001	Banholzer et al.		
	29.	US 6,455,524	09/24/2002	Bozung et al.		
	30.	US 6,635,629	10/21/2003	Raymond et al.		

FOREIGN PATENT DOCUMENTS Foreign Patent Document Country Code³ - Number⁶ - Kind Code⁵ (if known) Publication Date Name of Patentee or Examiner Pages, Columns, Lines. MM-DD-YYYY Applicant of Cited Document Where Relevant Passages or Relevant Figures Appear 31. EP 115394 B1 06/28/1989 Guindon, et al 08/16/1998 32. EP 136893 B1 Fortin, et al EP 138481 B1 06/26/1991 Fortin, et al 34. EP 140709 B1 04/03/1991 Atkinson, et al. 35. EP 429187 B1 01/05/1994 Bourke et al. 04/28/2004 EP 934745 B1 Kennedy 36. 37. GB 2,240,472 A 08/07/1991 Masterson 38. WO 91/04030 A1 04/04/1991 Davnes et al. 30 WO 96/25935 A1 08/29/1996 Nvce

Examiner		Date		1
Signature		Considered		
*EXAMINER:	Initial if reference considered, whether or not citation is in conformance with MPEP 609.	Draw line through	citation if not in conformance and not considered	Include copy

of this form with next communication to applicate. Applicant's unique citation designation number (optional). "See Kinds Codes of USF70 Partner Documents at www stops go or or MFPF 99) to 4. Their Office that award the documents, by the two-leter code (WHO Standard ST.3). "For Japanese pointed document, the indication of the year of the right of the Empirery among the code of the Empirery among the code of the Code of USF70 Partner Code (WHO Standard ST.3). "For Japanese pointed document, the indication of the year of the right of the Empirery among the code of the Code of the Code of the Empirery among the Code of the Code

check melt, her if English language Translations in attached.

This obligation of information is required to Obtain or return a board's by the golds: which is to fife (and by the USPTO to present) an application. Confidentiality is generated by 30 U.S.C. 12 and 37 CFR 1.14 This obligation is included in a sectionated to all 20 below to complete, belonging pattering, represent an application. Confidentiality is agreemed by 30 U.S.C. 12 and 37 CFR 1.14 This obligation is a requirement to the income of time you require to complete this form mild'or suggestion for reducing the state, may be about be zero to the Colle formation offices, 15 P. Stress and Tobermark Offices, p. 0. Bost 1649, Abstrassiva (AUSL-114-145 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Friends, P.O. Best 1459, Abstrassified, VALD-1131-1460.

The property of the confidence of the c

PTO/SB/08 (07/05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

				Complete if Known		
Substitute for form 1449/PTO INFORMATION DISCLOSURE				Application Number	10/698,076	
				Filing Date	October 29, 2003	
STATEMENT BY APPLICANT		First Named Inventor	Cynthia B. Robinson			
(Use a.	(Use as many sheets as necessary)		Art Unit	1617		
			Examiner Name	Umamaheswari Ramachandran		
Sheet	3	Of	4	Attorney Docket Number	30775-714.201	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	40.	ABOU-GHARBIA, et al. Synthesis of dehydroepiandrosterone sulfatide and 16 alphahalogenated steroids. J Pharm Sci. 1981; 70(10):1154-7.	
	41.	BUNDGAARD et al. Esters of N,N-disubstituted 2-hydroxyacetamides as a novel highly biolabile prodrug type for carboxylic acid agents. J. Med Chem. 1987; 30(3):451-454.	
	42.	DASHTAKI et al. Dehydroepiandrosterone and Analogs Inhibit DNA Binding of AP-1 and Airway Smooth Muscle Proliferation. J. Pharmacol. EXD. Thera. 285(2):876-83 (1998).	
	43.	FOLKERS, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A. 1990;87(22):8931-4.	
	44.	GREENBERG, et al. Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol. 1990; 30(7):596-608.	
	45.	ISHIHARA, et al. Gas chromatographic determination of degradation products and stability of dehydroepiandrosterone. Drug Develop. Ind. Pharm. 1979; 5(3):263-275.	
	46.	MERCK Index Monograph No. 7710. 11th Ed. 1989.	
	47.	MOHAN, et al. Dehydroepiandrosterone and related steroids inhibit mitochondrial respiration in vitro. Int J Biochem. 1989; 21(10): 1103-7.	
	48.	MORTENSEN, et al. Coenzyme Q10: clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure. Int J Tissue React. 1990;12(3):155-62.	
	49.	NAKAGAWA, et al. The effect of grinding and drying on the solid state stability of sodium prasterone sulfate. Chem. Pharm. Bull. 1982; 30(1):242-8.	

Examiner	Date
Signature	Considered
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.	Draw line through citation if not in conformance and not considered. Include copy
- 5 at 1 - 5	

of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Octoe of USFTO Patent Decuments as www. supra gov or MPEP*
90.10 **Either Office that issued the document, by the two-better code (PMPD Standard ST.). *For Japanese patent documents, the indication of the year of the "rich Emprove must proceed the serial number of the patent documents. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a chock mark her of English Banaguage Transition is standard.

check mak her of English Imprages Transitions is stateded.

To Till 8 of Section 1 and 19 of Till 8 of Til

PTO/SB/08 (07/05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

				Complete if Known		
Substitute f	or form 144	9/PTO		Application Number	10/698,076	
INFORMATION DISCLOSURE				Filing Date	October 29, 2003	
STATEMENT BY APPLICANT			LICANT	First Named Inventor	Cynthia B. Robinson	
(Use as many sheets as necessary)		Art Unit	1617			
	(Use as many sheets as necessary)		Examiner Name	Umamaheswari Ramachandran		
Sheet	4	Of	4	Attorney Docket Number	30775-714.201	

		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	
Examiner Initials*	Cite No.1	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	50.	NAKAGAWA, et al. the properties of water of crystalization of sodium prasterone sulfate. Chem. Pharm. Bull. 1981; 29(5):1466-9.	
	51.	SAARI, et al. Synthesis and antihypertensive activity of some ester progenitors of methyldopa. J. Med. Chem. 1978; 21(8):746-753.	
	52.	SAKAMOTO, et al. Studies on prodrugs. II. Preparation and characterization of (S- substituted 2-oxo-1,3-dioxolen-4-yl)methyl esters of ampicillin. Chem. Pharm. Bull. 1984; 32(6):2241-2248.	

		UNPUBLISHED PATENT APPLICATIONS	
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	
Examiner	Cite	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	
Initials*	No.1	publisher, city and/or country where published.	1
		LEONARD, et al. US Patent Application No. 10/462,927, entitled "Dihydrate	
	53.	dehydroepiandrosterone and methods of treating asthma or chronic obstructive	
	55.	pulmonary disease using compositions thereof," filed June 17, 2003. (WSGR Reference	
	1	No. 30775-722.201)	ı

Examiner		Date	
Signature		Considered	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy			

*EXAMINER: Initial Erfertenes considered, whether or not clusten is no conformance with NPID 600. Date line through citation for nit conformance and not considered Include copy of the form with nave commissation to applicable. "Applicative inseging." Applicative inseging citation designation under optional." See Excitation Code of ISETIO TRUE Decembers as wew uptop or NFEP 901.04. "Extra Collice that issued the document, by the two-learness on NFEP 901.04." Extra Collice that issued the document, by the two-learness of the preparate designation of the preparate designation in the preparate designation is indicated on the document ander WIDS ORGANICATION of the Emprover must proceed the testin interest of the preparate designation is indicated on the document under WIDS ORGANICATION 1.05 of the Emprover organication that the complete operation of the preparate designation is organicated to the complete operation of the preparate designation of the preparate organication is organicated to the preparate organication of the preparate organication of the preparate organication or the preparate organication from the DESTRO Time will vary depending upon the individual cause. Any comments on the amount of taxe you require to complete this form and/or suggestions for reduction of the preparate organication or the preparate organication from the DESTRO Time will vary depending upon the individual cause. Any comments on the amount of taxe you require to complete this form and/or suggestion for reducing the hardon produce of the preparate organication or the preparate organication of the preparate organication or the preparate organication or the preparate organication or the preparate organication organication organication orga